Byron Black, a 68-year-old man on Tennessee's death row, has filed a petition with the Tennessee Supreme Court to halt his ...

Clinical trial processes lag behind scientific and technological advances. While the science and tools exist to run faster, more inclusive, and efficient trials, outdated mindsets, rigid protocols, ...

A man in his 50s had normal blood pressure measured at the health examination center, but showed cardiac hypertrophy and ...

Pulmonary embolism (PE) remains one of the leading causes of maternal mortality. At the French Thoracic Society Spring Days ...

Using similar criteria, the study of men born in 1913 reported incidence rates of “manifest” heart failure of 1.5, 4.3, and 10.2 new cases/1000 in men aged 50–54, 55–60, and 61–67 years, respectively.

The British Heart Foundation said more than a million people in the UK had heart failure An at-home 'foot-recognition' scanner could prevent heart failure hospitalisations, a study has found. The ...

Hadassah doctors performed the country’s first-ever complete artificial heart transplant on a 63-year-old patient, offering new hope for patients with severe heart failure.

[1,2] One of the oldest ancillary diagnostic tests was first described in 1971 in the Framingham Heart Study, where one of the major criteria for the diagnosis of heart failure was a ≥4.5 kg (10 ...

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 inhibitors – AstraZeneca's Farxiga ...

Many of the compensatory biochemical mechanisms activated during early heart failure, such as neurohormonal activation and cytokine and growth-factor upregulation, induce myocellular hypertrophy ...

AI foot scanner recognises warning signs of heart failure to keep people out of hospital, researchers say. The device takes and analyses almost 2,000 pictures a minute, in a similar manner to ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, ...